ES2459565B2 - Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurinic groups, and their use as anticancer agents - Google Patents
Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurinic groups, and their use as anticancer agents Download PDFInfo
- Publication number
- ES2459565B2 ES2459565B2 ES201430048A ES201430048A ES2459565B2 ES 2459565 B2 ES2459565 B2 ES 2459565B2 ES 201430048 A ES201430048 A ES 201430048A ES 201430048 A ES201430048 A ES 201430048A ES 2459565 B2 ES2459565 B2 ES 2459565B2
- Authority
- ES
- Spain
- Prior art keywords
- phenylmethylpurinic
- dioxolanylalkyl
- groups
- secondary amines
- anticancer agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Sulfonamidas derivadas de aminas secundarias con grupos 1,3-dioxolanilalquílicos y fenilmetilpurínicos, y su utilización como agentes anticancerígenos.#La presente invención se refiere a derivados de sulfonilanilina, o-, m- y p-sustituidos, y/o 1-dimetilaminonaftalen-5-sulfonilanilina (dansilanilina) en los que el átomo de nitrógeno de la anilina se encuentra alquilado por un grupo 2-(1,3-dioxolan-2-il)alquílico y además, el anillo bencénico de la anilina se encuentra alquilado por el grupo 2-fenilmetilpurínico sustituido con halógenos en la purina, unido a través del enlace N-9 de la purina cuando se parta de la sulfonilanilina o-, m- y p-sustituida, y a través de los enlaces N-9 o N-7 de la purina cuando se parta de la dansilanilina; a su procedimiento de síntesis y a su uso como medicamento para el tratamiento de cáncer.Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurine groups, and their use as anticancer agents. # The present invention relates to sulfonilaniline derivatives, o-, m- and p-substituted, and / or 1-dimethylaminonaphthalen 5-sulfonilanilina (dansilanilina) in which the nitrogen atom of the aniline is alkylated by a group 2- (1,3-dioxolan-2-yl) alkyl and also, the benzene ring of the aniline is rented by the 2-phenylmethylpurinic group substituted with halogens in the purine, linked through the purine N-9 bond when starting from the o-, m- and p-substituted sulfonilaniline, and through the N-9 or N-7 bonds of purine when starting from dansilaniline; to its synthesis procedure and its use as a medicine for the treatment of cancer.
Description
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430048A ES2459565B2 (en) | 2014-01-20 | 2014-01-20 | Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurinic groups, and their use as anticancer agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430048A ES2459565B2 (en) | 2014-01-20 | 2014-01-20 | Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurinic groups, and their use as anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2459565A1 ES2459565A1 (en) | 2014-05-09 |
| ES2459565B2 true ES2459565B2 (en) | 2014-09-29 |
Family
ID=50630470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201430048A Active ES2459565B2 (en) | 2014-01-20 | 2014-01-20 | Sulfonamides derived from secondary amines with 1,3-dioxolanylalkyl and phenylmethylpurinic groups, and their use as anticancer agents |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2459565B2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2334747B2 (en) * | 2008-08-07 | 2011-06-10 | Universidad De Granada | NEW (RS) - 7- O 9- (1,2,3,5- TETRAHIDRO-4,1-BENZOCAZEPIN-3-IL) -7H O9H-PURINS WITH ANTITUMORAL ACTIVITY. |
-
2014
- 2014-01-20 ES ES201430048A patent/ES2459565B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2459565A1 (en) | 2014-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012313A (en) | OXISTEROLS AND METHODS OF USE THEREOF. | |
| MX373318B (en) | 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE-FOR USE IN THE TREATMENT OF CANCER. | |
| CO2017006214A2 (en) | Quinazoline derivatives used to treat HIV | |
| MX2016011632A (en) | Azaspiro derivatives as trpm8 antagonists. | |
| DOP2016000299A (en) | PIRROLIDINE-2,5-DIONA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS IDO1 INHIBITORS | |
| CL2016002148A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutically acceptable pharmaceutical compositions and compositions prepared therefrom. | |
| CL2014001793A1 (en) | Compounds derived from substituted 1,3,5-triazines and their salts, as inhibitors of mutant idh2; pharmaceutical composition that includes them; and its use for the treatment of cancer. | |
| DOP2015000270A (en) | POTENTIAL OF INHIBITORS OF THE HOMOLOGIST OF ZESTE | |
| CL2016001287A1 (en) | Substituted benzamides and procedure for use | |
| CO2018004857A2 (en) | Dihydroimidazopirazinone derivatives used in cancer treatment | |
| MX2017009505A (en) | 9h-pyrrolo-dipyridine derivatives. | |
| DOP2017000289A (en) | NUCLEAR RECEIVER MODULATORS | |
| CL2014002505A1 (en) | Compounds derived from substituted pyridopyrimidine, as inhibitors of flt3; pharmaceutical formulation that includes them; and its use for the treatment of malignant hematologic tumors such as leukemia, autoimmune diseases and malignant solid tumors. | |
| UY35129A (en) | HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE LIGANDS D1 | |
| GT201600269A (en) | DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE | |
| CL2018003121A1 (en) | Zeste 2 homolog enhancer inhibitors. | |
| CR20160374A (en) | CYCLOPENTANES REPLACED IN 1,2 AS AN OGREXINE RECEIVER ANTAGONISTS | |
| DOP2018000062A (en) | PIRIDINONA DICABOXAMIDS FOR USE AS BROMODOMINUM INHIBITORS | |
| MX2017000183A (en) | Benzoxazinone amides as mineralocorticoid receptor modulators. | |
| GT201700058A (en) | 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-ILO COMPOUNDS AND USES THEREOF | |
| MX2019012938A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor. | |
| CR20150096A (en) | TRANS-CLOMIFEN FORMULATIONS AND USES OF THE SAME | |
| UY35708A (en) | NEW COMPOUNDS AS ANTAGONISTS OF THE LISOPHOSPHYTIDIC ACID RECEPTOR | |
| CL2019001991A1 (en) | Estrogen receptor modulators. | |
| UY37191A (en) | DIBENZOFURAN DERIVATIVES FOR USE AS BROMODOMINUM INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2459565 Country of ref document: ES Kind code of ref document: B2 Effective date: 20140929 |